Citations

We’ve gathered published citations for the past many years so that researchers can easily review at their convenience from among the thousands of published articles, how they might use our products in detail or apply these ideas to their own novel thinking for new research.

Search through, read and share our information rich citations below!

Contact us with any questions.

4724 total record number 96 records this year

To narrow your search, use one or more of the following search menus below.

To search by keyword, you may search by the cell/animal/assay/protein/research or publication
Page 11 out of 473
4724 citations found

Renal macrophages monitor and remove particles from urine to prevent tubule obstruction

He, J;Cao, Y;Zhu, Q;Wang, X;Cheng, G;Wang, Q;He, R;Lu, H;Weng, Y;Mao, G;Bao, Y;Wang, J;Liu, X;Han, F;Shi, P;Shen, XZ;

Product: Diphtheria Toxin, Unnicked, from Corynebacterium diphtheriae

Immunoswitch Nanomodulators Enable Active Targeting and Selective Proliferation of Regulatory T Cells for Multiple Sclerosis Therapy

Wang, X;Liu, Z;Wang, D;Zhang, Y;Zhang, H;Xue, F;Wang, X;Tang, Z;Han, X;

Product: Pertussis Toxin from B. pertussis, Lyophilized in Buffer

Peripherally derived myeloid cells induce disease-dependent phenotypic changes in microglia

Thougaard, E;Carney, B;Wlodarczyk, A;Brambilla, R;Lambertsen, KL;

Product: Pertussis Toxin from B. pertussis, Lyophilized (Salt-Free)

  • 2.3 Experimental autoimmune encephalomyelitis

    Mice were induced with experimental autoimmune encephalomyelitis (EAE) following a protocol well established in the laboratory (Brambilla et al., 2011; Madsen et al., 2020). Briefly, on day 0 and 2, pertussis toxin (PTX, List Biological Laboratories, #181) diluted in PBS was injected intraperitoneally (500 μg/mouse). On day 1, myelin oligodendrocyte glycoprotein peptide 35–55 (MOG35–55, Bio-Synthesis, #A9349-1) emulsified in complete Freund’s adjuvant was injected subcutaneously (0.33 mg/mouse). …

    Product #181 – Pertussis Toxin from B. pertussis, Lyophilized (Salt-Free)

Tonabersat Significantly Reduces Disease Progression in an Experimental Mouse Model of Multiple Sclerosis

Kwakowsky, A;Chawdhary, B;de Souza, A;Meyer, E;Kaye, AH;Green, CR;Stylli, SS;Danesh-Meyer, H;

Product: Pertussis Toxin from B. pertussis, Lyophilized in Buffer

  • 4.2. EAE Model Preparation

    The detailed methods used for the EAE procedure are as described previously [25]. Briefly, EAE was induced by immunization of mice with 200 mg of MOG35–55-CFA solution (Myelin Oligodendrocyte Glycoprotein peptide in Complete Freund’s Adjuvant) injected subcutaneously near the inguinal lymph nodes and the axillary lymph nodes on the left side of the mouse, followed by an intraperitoneal injection administering 500 ng of Pertussis toxin (95008-6906; List Biological Laboratories Inc., Campbell, CA, USA) in phosphate-buffered saline (PBS), pH 7.4, on days 0, 2, and 7. Repeat intraperitoneal injections were always carried out on the opposite side of the previous injection. Mice were anaesthetized with a 2–2.5% isoflurane with an oxygen flow of 2 L per minute to minimise pain and distress. Tonabersat was administered via single daily intraperitoneal injections at doses of 0.2, 0.4 and 0.8 mg/kg, either following early dosing (days 3–15 post-inoculation) or late dosing (days 8–15 post-inoculation) regime. …

    Author did not specify which List Labs Pertussis Toxin was utilized. List Labs provides the following Pertussis Toxin products:
    Product #180 – Pertussis Toxin from B. pertussis, Lyophilized in Buffer
    Product #181 – Pertussis Toxin from B. pertussis, Lyophilized (Salt-Free)
    Product #179A – Pertussis Toxin from B. pertussis (in Glycerol)

Glycosylation-modified antigens as a tolerance-inducing vaccine platform prevent anaphylaxis in a pre-clinical model of food allergy

Cao, S;Maulloo, CD;Raczy, MM;Sabados, M;Slezak, AJ;Nguyen, M;Solanki, A;Wallace, RP;Shim, HN;Wilson, DS;Hubbell, JA;

Product: Cholera Toxin (AZIDE-FREE) from Vibrio cholerae

  • Evaluation of i.v. administration of BLG-p(Man) in a mouse model of BLG sensitization

    This BLG sensitization model was adapted from ref. 27 and 28. Beginning at 2 weeks of age, SPF C3H/HeJ mice were treated with a
    mixture of antibiotics (Abx). For the first week before weaning, mice were treated with 100 mL Abx solution once daily, including kanamycin (4 mg/mL), gentamicin (0.35 mg/mL), colistin (8500 U/mL), metronidazole (2.15 mg/mL), and vancomycin (0.45 mg/mL)
    (Sigma-Aldrich). After weaning, mice were given drinking water supplemented with a 50-folded dilution of the same Abx solution
    except vancomycin, which was maintained at 0.45 mg/mL, throughout the duration of the experiment. Prior to weaning, on day 1
    and day 5 after first oral gavage of Abx, the mice were i.v. administered with PBS, or 2 mg BLG in the form of unmodified (free)
    BLG or BLG-p(Man) per 10 g body weight. Right after weaning, mice were sensitized weekly for 5 weeks by intragastric gavage
    with BLG (20 mg per 10 g body weight) (Sigma-Aldrich) and cholera toxin (CT, 10 mg per 10 g body weight) (List Biologicals, Campbell, CA). …

    Product #100B – Cholera Toxin (AZIDE-FREE) from Vibrio cholerae

Flotillins affect LPS-induced TLR4 signaling by modulating the trafficking and abundance of CD14

Matveichuk, O;Ciesielska, A;Hromada-Judycka, A;Nowak, N;Ben Amor, I;Kwiatkowska, K;

Product: LPS from Escherichia coli O111:B4

A bead-based multiplex assay covering all coronaviruses pathogenic for humans for sensitive and specific surveillance of SARS-CoV-2 humoral immunity

Stern, D;Meyer, TC;Treindl, F;Mages, HW;Krüger, M;Skiba, M;Krüger, JP;Zobel, CM;Schreiner, M;Grossegesse, M;Rinner, T;Peine, C;Stoliaroff-Pépin, A;Harder, T;Hofmann, N;Michel, J;Nitsche, A;Stahlberg, S;Kneuer, A;Sandoni, A;Kubisch, U;Schlaud, M;Mankertz, A;Schwarz, T;Corman, VM;Müller, MA;Drosten, C;de la Rosa, K;Schaade, L;Dorner, MB;Dorner, BG;

Product: Pertussis Toxin from B. pertussis, Lyophilized (Salt-Free)

The long non-coding RNA HOTAIR contributes to joint-specific gene expression in rheumatoid arthritis

Elhai, M;Micheroli, R;Houtman, M;Mirrahimi, M;Moser, L;Pauli, C;Bürki, K;Laimbacher, A;Kania, G;Klein, K;Schätzle, P;Bertoncelj, MF;Edalat, SG;Keusch, L;Khmelevskaya, A;Toitou, M;Geiss, C;Rauer, T;Sakkou, M;Kollias, G;Armaka, M;Distler, O;Ospelt, C;

Product: LPS from Escherichia coli J5 (Rc)

  • SF stimulation

    SF were stimulated with human recombinant TNF (10 ng/ml; R&D Systems), human recombinant IL1β (1 ng/ml; R&D Systems), lipopolysaccaride (LPS) from Escherichia coli J5 (100 ng/ml; List Biological Laboratories), polyI-C (PIC) (10 μg/ml; InvivoGen), bacterial lipopeptide (bLP) palmitoyl-3-cysteine-serine-lysine-4 (300 ng/ml; InvivoGen) or human recombinant TGFβ (10 ng/ml; R&D Systems) for 24 h. …

    Product #301 – LPS from Escherichia coli J5 (Rc)

Horizontal gene transfer shapes pathogenic bacteria in multiple sclerosis

Yamamura, T;Takewaki, D;Kiguchi, Y;Masuoka, H;Manu, M;Raveney, B;Narushima, S;Kurokawa, R;Ogata, Y;Kimura, Y;Sato, N;Ozawa, Y;Yagishita, S;Araki, T;Miyake, S;Sato, W;Suda, W;

Product: Pertussis Toxin from B. pertussis, Lyophilized in Buffer

Small-molecule targeting AMPA-mediated excitotoxicity has therapeutic effects in mouse models for multiple sclerosis

Zhai, D;Yan, S;Samsom, J;Wang, L;Su, P;Jiang, A;Zhang, H;Jia, Z;Wallach, I;Heifets, A;Zanato, C;Tseng, CC;Wong, AHC;Greig, IR;Liu, F;

Product: Pertussis Toxin from B. pertussis, Lyophilized in Buffer